210 related articles for article (PubMed ID: 22452784)
1. Oestrogen causes ATBF1 protein degradation through the oestrogen-responsive E3 ubiquitin ligase EFP.
Dong XY; Fu X; Fan S; Guo P; Su D; Dong JT
Biochem J; 2012 Jun; 444(3):581-90. PubMed ID: 22452784
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells.
Zhao KW; Sikriwal D; Dong X; Guo P; Sun X; Dong JT
Biochem J; 2011 Jul; 437(2):323-33. PubMed ID: 21542805
[TBL] [Abstract][Full Text] [Related]
3. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth.
Urano T; Saito T; Tsukui T; Fujita M; Hosoi T; Muramatsu M; Ouchi Y; Inoue S
Nature; 2002 Jun; 417(6891):871-5. PubMed ID: 12075357
[TBL] [Abstract][Full Text] [Related]
4. Ligand-dependent transcription of estrogen receptor alpha is mediated by the ubiquitin ligase EFP.
Nakajima A; Maruyama S; Bohgaki M; Miyajima N; Tsukiyama T; Sakuragi N; Hatakeyama S
Biochem Biophys Res Commun; 2007 May; 357(1):245-51. PubMed ID: 17418098
[TBL] [Abstract][Full Text] [Related]
5. Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.
Dong XY; Guo P; Sun X; Li Q; Dong JT
J Biol Chem; 2011 Apr; 286(16):13879-90. PubMed ID: 21367855
[TBL] [Abstract][Full Text] [Related]
6. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic analysis of hormone-sensitive patient-derived endometrial cancer spheroid culture defines Efp as a proliferation modulator.
Yang C; Ikeda K; Horie-Inoue K; Sato W; Hasegawa K; Takeda S; Itakura A; Inoue S
Biochem Biophys Res Commun; 2021 Apr; 548():204-210. PubMed ID: 33647797
[TBL] [Abstract][Full Text] [Related]
8. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation.
Zou W; Wang J; Zhang DE
Biochem Biophys Res Commun; 2007 Mar; 354(1):321-7. PubMed ID: 17222803
[TBL] [Abstract][Full Text] [Related]
9. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase.
Zou W; Zhang DE
J Biol Chem; 2006 Feb; 281(7):3989-94. PubMed ID: 16352599
[TBL] [Abstract][Full Text] [Related]
10. Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer.
Sakuma M; Akahira J; Suzuki T; Inoue S; Ito K; Moriya T; Sasano H; Okamura K; Yaegashi N
Gynecol Oncol; 2005 Dec; 99(3):664-70. PubMed ID: 16140366
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-responsive RING finger protein controls breast cancer growth.
Horie K; Urano T; Ikeda K; Inoue S
J Steroid Biochem Mol Biol; 2003 Jun; 85(2-5):101-4. PubMed ID: 12943693
[TBL] [Abstract][Full Text] [Related]
12. Efp promotes in vitro and in vivo growth of endometrial cancer cells along with the activation of nuclear factor-κB signaling.
Sato W; Ikeda K; Urano T; Abe Y; Nakasato N; Horie-Inoue K; Takeda S; Inoue S
PLoS One; 2018; 13(12):e0208351. PubMed ID: 30586414
[TBL] [Abstract][Full Text] [Related]
13. A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15.
Nakasato N; Ikeda K; Urano T; Horie-Inoue K; Takeda S; Inoue S
Biochem Biophys Res Commun; 2006 Dec; 351(2):540-6. PubMed ID: 17069755
[TBL] [Abstract][Full Text] [Related]
14. Efp as a primary estrogen-responsive gene in human breast cancer.
Ikeda K; Orimo A; Higashi Y; Muramatsu M; Inoue S
FEBS Lett; 2000 Apr; 472(1):9-13. PubMed ID: 10781795
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-responsive finger protein as a new potential biomarker for breast cancer.
Suzuki T; Urano T; Tsukui T; Horie-Inoue K; Moriya T; Ishida T; Muramatsu M; Ouchi Y; Sasano H; Inoue S
Clin Cancer Res; 2005 Sep; 11(17):6148-54. PubMed ID: 16144914
[TBL] [Abstract][Full Text] [Related]
16. Efp/TRIM25 and Its Related Protein, TRIM47, in Hormone-Dependent Cancers.
Azuma K; Inoue S
Cells; 2022 Aug; 11(15):. PubMed ID: 35954308
[TBL] [Abstract][Full Text] [Related]
17. Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer.
Sato J; Azuma K; Kinowaki K; Ikeda K; Ogura T; Takazawa Y; Kawabata H; Kitagawa M; Inoue S
Clin Breast Cancer; 2021 Oct; 21(5):399-407.e2. PubMed ID: 33386231
[TBL] [Abstract][Full Text] [Related]
18. Analysis of estrogen-responsive finger protein expression in benign and malignant human breast.
Thomson SD; Ali S; Pickles L; Taylor J; Pace PE; Lymboura M; Shousha S; Coombes RC
Int J Cancer; 2001 Jan; 91(2):152-8. PubMed ID: 11146438
[TBL] [Abstract][Full Text] [Related]
19. Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp. Co-localization with estrogen receptor mRNA in target organs.
Orimo A; Inoue S; Ikeda K; Noji S; Muramatsu M
J Biol Chem; 1995 Oct; 270(41):24406-13. PubMed ID: 7592654
[TBL] [Abstract][Full Text] [Related]
20. Systemic distribution of estrogen-responsive finger protein (Efp) in human tissues.
Shimada N; Suzuki T; Inoue S; Kato K; Imatani A; Sekine H; Ohara S; Shimosegawa T; Sasano H
Mol Cell Endocrinol; 2004 Apr; 218(1-2):147-53. PubMed ID: 15130519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
